CRP抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Flow cytometric analysis of MCF-7 cells using CRP mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human liver cancer tissues using CRP mouse mAb with DAB staining.    

  
  

C-reactive protein (CRP), a pentameric acute-phase protein synthesized by the liver, plays a central role in innate immunity by binding to pathogens or damaged cells to activate the complement system. Discovered in 1930. CRP’s name derives from its interaction with pneumococcal C-polysaccharide. Elevated CRP levels in blood (>10 mg/L) correlate strongly with inflammation, infections, or tissue injury, making it a widely used clinical biomarker.

CRP antibodies, specifically developed to detect and quantify this protein, are critical in diagnostic assays. Monoclonal antibodies, generated via hybridoma technology, target specific epitopes on CRP’s cyclic pentameric structure, ensuring high specificity. Polyclonal antibodies, though less specific, provide broader epitope recognition. These antibodies underpin immunoassays like ELISA, turbidimetry, and lateral flow tests, enabling rapid CRP measurement in settings ranging from routine inflammation monitoring to cardiovascular risk assessment (via high-sensitivity CRP/hs-CRP).

Advancements in antibody engineering, such as recombinant or humanized antibodies, have enhanced assay precision and reduced cross-reactivity. Despite challenges like CRP’s pH-dependent conformational changes affecting antibody binding, CRP antibodies remain indispensable tools in both clinical diagnostics and research exploring CRP’s roles in autoimmune diseases, atherosclerosis, and beyond.